



HAL
open science

Bioactive Bromotyrosine Derivatives from the Pacific Marine Sponge *Suberea clavata* (Pulitzer-Finali, 1982)

Ali Al-Mourabit, Damien Lacroix, Sylvain Petek, Amr El-Demerdash, Rozenn Trepos, Tinihauarii Mareva Leu, Cristina Florean, Marc Diederich, Claire Hellio, Cécile Debitus, et al.

► To cite this version:

Ali Al-Mourabit, Damien Lacroix, Sylvain Petek, Amr El-Demerdash, Rozenn Trepos, et al.. Bioactive Bromotyrosine Derivatives from the Pacific Marine Sponge *Suberea clavata* (Pulitzer-Finali, 1982). *Marine drugs*, 2021, 19 (3), pp.143. 10.3390/md19030143 . hal-03319162

HAL Id: hal-03319162

<https://hal.science/hal-03319162v1>

Submitted on 12 Aug 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

Article

Bioactive Bromotyrosine Derivatives from the Pacific Marine Sponge *Suberea clavata* (Pulitzer-Finali, 1982)

Céline Moriou¹, Damien Lacroix¹, Sylvain Petek^{2,*}, Amr El-Demerdash¹, Rozenn Trepos², Tinihaurii Mareva Leu³, Cristina Florean⁴, Marc Diederich⁵, Claire Hellio², Cécile Debitus² and Ali Al-Mourabit^{1,*}

¹ CNRS, Institut de Chimie des Substances Naturelles, Université Paris-Saclay, F-91190 Gif-sur-Yvette, France; celine.moriou@cnrs.fr (C.M.); crespipharma@gmail.com (D.L.); eldemerdash555@gmail.com (A.E.-D.)

² IRD, CNRS, Ifremer, LEMAR, Univ Brest, F-29280 Plouzane, France; rozenn.trepos@gmail.com (R.T.); claire.hellio@univ-brest.fr (C.H.); cecile.debitus@ird.fr (C.D.)

³ IRD, Ifremer, ILM, EIO, Univ de la Polynésie française, F-98713 Papeete, French Polynesia; mareva.leu@gmail.com

⁴ Laboratoire de Biologie Moléculaire et Cellulaire du Cancer, Hôpital Kirchberg, 9, rue Edward Steichen, L-2540 Luxembourg, Luxembourg; cristina.florean@lbmcc.lu

⁵ Department of Pharmacy, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Korea; marcdiederich@snu.ac.kr

* Correspondence: sylvain.petek@ird.fr (S.P.); ali.almourabit@cnrs.fr (A.A.-M.); Tel.: +33-298-498-651 (S.P.); +33-169-824-585 (A.A.-M.)

Abstract: Chemical investigation of the South-Pacific marine sponge *Suberea clavata* led to the isolation of eight new bromotyrosine metabolites named subereins 1–8 (2–9) along with twelve known co-isolated congeners. The detailed configuration determination of the first representative major compound of this family 11-*epi*-fistularin-3 (11*R*,17*S*) (**1**) is described. Their chemical characterization was achieved by HRMS and integrated 1D and 2D NMR (nuclear magnetic resonance) spectroscopic studies and extensive comparison with literature data. For the first time, a complete assignment of the absolute configurations for stereogenic centers C-11/17 of the known members (11*R*,17*S*) 11-*epi*-fistularin-3 (**1**) and 17-deoxyfistularin-3 (**10**) was determined by a combination of chemical modifications, Mosher's technology, and ECD spectroscopy. Consequently, the absolute configurations of all our new isolated compounds 2–9 were determined by the combination of NMR, Mosher's method, ECD comparison, and chemical modifications. Interestingly, compounds 2–7 were obtained by chemical transformation of the major compound 11-*epi*-fistularin-3 (**1**). Evaluation for acetylcholinesterase inhibition (AChE), DNA methyltransferase 1 (DNMT1) modulating activity and antifouling activities using marine bacterial strains are also presented.

Keywords: sponge; Verongiida; *Suberea clavata*; bromotyrosine; fistularin-3; acetylcholinesterase inhibition; antifouling



Citation: Moriou, C.; Lacroix, D.; Petek, S.; El-Demerdash, A.; Trepos, R.; Leu, T.M.; Florean, C.; Diederich, M.; Hellio, C.; Debitus, C.; et al. Bioactive Bromotyrosine Derivatives from the Pacific Marine Sponge *Suberea clavata* (Pulitzer-Finali, 1982). *Mar. Drugs* **2021**, *19*, 143. <https://doi.org/10.3390/md19030143>

Academic Editor: Bill J. Baker

Received: 14 February 2021

Accepted: 2 March 2021

Published: 6 March 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

The Verongiida order is well known for producing highly diversified brominated metabolites, which are biogenetically linked to tyrosine. A large number of bromotyrosine derivatives, including “dimeric” spiro-isoxazoline alkaloids, phenolic oximino amides, and tetrameric macrocyclic bastadins have been reported [1]. Many of these metabolites possess diverse biological activities and also ecological significance. These specialized metabolites play a crucial role in the interactions between organisms and with their environment in their ecosystem. Bromotyrosines compounds are chemical markers of the Verongiida order [2]. They are of great interest for chemical exploration: although bromotyrosine metabolites were mainly isolated from sponge species belonging to Verongiida order, it is worth to note that fistularin-3 was very recently identified by Nicacion et al. in cultures of the marine bacterium *Pseudovibrio denitrificans* Ab134 isolated from the sponge *Arenosclera brasiliensis* [3]. The very special interest of this result lies in the sustainable

supply potential of fistularin for further use. Nevertheless, the association of the bacterium *Pseudovibrio denitrificans* with a sponge from the order Haplosclerida deflects the presence of bromotyrosine specifically in the sponges of the order Verongiida. The identification of the bromotyrosine-derived alkaloids agelorins A-B and 11-*epi*-fistularin-3 from an Australian *Agelas oroides* (order Agelasida) by König et al. [4] is another exception to the idea that these compounds are specifically associated with Verongiida sponges.

From a chemical ecology point of view, some of these polybrominated compounds have been suggested to undergo enzyme-mediated transformation into aeroplysinin-1 and dibromocyclohexadienone which could play an important role in the sponge's defense mechanism as antifeedant, antifouling, and also in response to tissue damage [5,6]. Regarding pharmacology, bromotyrosine derivatives have been shown to possess a myriad of biological potentialities including antimalarial [7], biocidal antifouling [8,9], antimicrobial [10], antimycobacterial [11], antiviral [12,13], and antifungal activities [14], cytotoxicity [15], specific histamine H-3 receptor antagonist [16], or enzyme inhibitors [17]. Several bromotyrosine derivatives analogs have been chemically synthesized and were able to inhibit human prostate cancer proliferation, invasion, and migration [18].

We previously discovered several brominated tyrosine congeners from the pacific marine sponge *Suberea ianthelliformis* with both chemical and ecological aspects [19]. As a part of our running program on the chemical exploration of pharmacologically active bromotyrosine products from *Suberea* marine sponges genus, we describe herein the isolation and structural assignment of eight new brominated tyrosine-containing metabolites (2–9), the absolute configuration determination of the known 11-*epi*-fistularin-3 (1) and 17-deoxyfistularin-3 (10) along with 11 other known derivatives from the sponge *Suberea clavata*. Biological evaluations for antibacterial and acetylcholinesterase (AChE) inhibitory activities and DNA methyltransferase 1 (DNMT1) modulating activity are described as well.

2. Results and Discussion

Isolation and Structure Elucidation

The sponge *Suberea clavata* [20,21] was collected in the Solomon Islands, extracted with a mixture of CH₂Cl₂/MeOH (1/1), and partitioned between n-BuOH and H₂O. A part of the butanolic extract (5 g) was submitted to reversed-phase C₁₈ SPE and eluted with successive solvents (H₂O; MeOH; CH₂Cl₂) to afford six fractions. Step-wise repetitive purifications using HPLC (high performance liquid chromatography) and SFC (supercritical fluid chromatography) separation methods gave eight new bromotyrosine compounds 2–9 (Figure 1) named subereins 1–8, as well as eleven known metabolites (Figure S2, supporting information) such as the major compound of the extract (3 g, 14.3%) 11-*epi*-fistularin-3 (1) [4], 17-deoxy-*epi*-fistularin-3 (10) [22], agelorins A and B (11–12) [4], 11-deoxyfistularin-3 (13) [23], 11,17-dideoxyfistularin-3 (14), 11-hydroxy-aerolithionin (15) [14], aerophobine 2 (16), aplysinamisin-1 (17) [24], 7R,11S [3,5-dibromo-4-[(2-oxo-5-oxazolidinyl)]methoxyphenyl]-2-oxazolidinone (18) [25], subereaphenol K (19) [26], and pseudoceralidinone A (20) [27], whose structures were confirmed by comparison of their spectroscopic data with those reported in the literature. We have recently reported the in vitro inhibition of DNMT1 by our 11-*epi*-fistularin-3 (1) and described docking studies of the determined configuration [28].




Figure 1. Structures and absolute configurations of the isolated compounds 1–10. The dotted rectangle groups the regioisomers two by two. The absolute configurations of all compounds were confirmed by the combination of NMR, Mosher's method, and ECD comparison.

The structure of the known *epi*-fistularin-3 (1) was confirmed by ^1H and ^{13}C NMR (nuclear magnetic resonance) data comparison with the literature [4,29]. In fact, similarities of ^1H and ^{13}C NMR spectra of fistularin-3 stereoisomers allow the room for confusion that exists regarding the absolute configurations of C-11 and C-17 carbons. The latter problem was pointed by Molinsky by studying samples from various sponges [29]. In the latter study, the configuration of C-11 was determined for different epimers. Finally, the C-17 configuration of all fistularin-3 isomers remains still undefined and the term isofistularin-3 is mainly used as generic name for undetermined fistularin-3 isomers so far. While the configuration of the verongidoic acid part (Figure 2) was established as 1(R), 6(S) for C-1 and C-6 by NMR spectroscopy and CD analysis [4,29,30], the absolute configurations at the two secondary carbinols C-11 and C-17 require precise determination. In the literature, this task was hampered by the presence of four secondary alcohols that significantly

complicated the co-determination of their absolute configuration by chemical modification and NMR studies on the native molecule without degradation. Suitable crystals for X-ray studies have never been obtained for any one of the stereoisomers of fistularin-3. Moreover, the carbon configuration also seems to vary depending on sponge species. The name 11-*epi*-fistularin-3 has been used to identify a molecule isolated from *Agelas oroides*, which was recognized as a 11(*R*) [29]. Fistularin-3 extracted from *Aplysina cauliformis* has an 11*S* configuration, leaving the configuration C-17 undetermined. Our contribution starts with the determination of the absolute configuration of both C-11 and C-17. The question that arose for us is which of the two epimers have we isolated by determining the configuration of C-11 on the one hand, and on the other hand if we can determine the configuration of C-17 for the first time.




Figure 2. (+)-1(*R*), 6(*S*), 1'(*R*), 6'(*S*), 11(*R*), 17(*S*)-fistularin-3 and Mosher AC (representation of the conformation of each MTPA esters and the resulting Δ^{SR} values (in Hz) for each of the protons).

The isomer that we have isolated **1** (Figure 2) showed similar NMR spectra and an optical rotation of $+148.0^\circ$ (c 1.0, MeOH) or $+169.0$ (0.2, acetone) compared to $+147^\circ$ (c 0.275, acetone) for fistularin-3. The first point was to make sure that our product is not a mixture of two C-11 epimers, as Molinsky demonstrated with *epi*-fistularin-3 [29]. Indeed, the zoom on C-11 and C-17 (see SI, Figure S3) of our C-13 NMR spectrum shows that our sample is indeed diastereomerically pure. As already noted in the literature, these bromotyrosine metabolites crystallize poorly and do not allow X-ray analysis, and indeed we tried the derivatization of the OH functionalities of **1** with crystallogenic groups such 3,5 dinitrobenzoic acid and camphanic acid without success. For both 1, 1', 11, 17-tetradinitrobenzoic ester and 1, 1', 11, 17-tetracamphanic derivatives, we were not able to obtain suitable crystals. We then decided to analyze the stereochemistry by alternative methods.

The known absolute configurations of the asymmetric centers (*R*)C-1, (*R*)C-1', (*S*)C-6 and (*S*)C-6' on the spiroisoxazole moiety was confirmed by comparison with NMR data

and the ECD spectrum that showed characteristic positive Cotton effects at 253 nm ($\Delta\epsilon +7.5$) and 285 nm ($\Delta\epsilon +8.0$) [31,32].

Following the method described by Molinsky [29], we hydrolyzed the *epi*-fistularin-3 (**1**) with aqueous trifluoroacetic acid at 120 °C overnight to obtain the 1,2-aminopropanediol bearing the C-2 carbinol corresponding to the C-11 of compound **1**. After derivatization with L-FDAA (2,4-dinitrophenyl-1-fluoro-L-alanine) and comparison with the C-2 configurations of the derivatized commercial standard aminodiols enantiomers, our sample was found to have the same retention time as the (+)-*R*-aminodiol standard, indicating that the C-11 of compound **1** is *R*.

At this stage, the configuration of the C-17 is still undetermined. To obtain the diastereomeric esters, 20 mg of **1** was reacted with (*R*) and (*S*)-methoxytrifluoromethylphenylacetyl chloride (MTPA-Cl) [33]. The reactions were performed in dichloromethane (DCM) in the presence of triethylamine or pyridine (10 equiv.) and a catalytic amount of 4-dimethylaminopyridine (DMAP). The monoester at position 17 was formed in minute quantity together with other polyesters at positions 1, 11, 17, and 1'. Reversed-phase HPLC (Sunfire C18, 10 × 150 mm, 5 μm; eluting with H₂O/Acetonitrile (98/2 to 0/100 in 35 min)) led to the pure desired monoesters. It should be noted that upon ester formation, the stereochemical descriptor of the MTPA-Cl stereocenter changes, because the COCl group has a Cahn–Ingold–Prelog (CIP) priority different from COOR. The Mosher esters obtained by reacting **1** with (*R*)- and (*S*)-MTPA chloride to yield the (*S*)- and (*R*)-MTPA esters respectively were analyzed using 1D and 2D NMR spectroscopy [33]. The difference in the chemical shift (δ^{SR}) was calculated for each of the analogous pairs of protons for both the (*S*)- and (*R*)-MTPA esters (Table 1). The positive values were assigned to the left side of the model (*R*₁) and the negative values were placed on the right side (*R*₂). By applying the Cahn–Ingold–Prelog system, the groups' priorities were assigned as 1 (OH), 2 (C-18), 3 (C-15/15'), and 4 (H), and the absolute configuration at C-17 was determined as (*S*) for the first time.

Table 1. $\Delta\delta$ ($=\delta_S-\delta_R$) (at 300 MHz) data for the *S*- and *R*-MTPA-*epi*-fistularin-3 esters.

Position	δ_S -Ester (ppm)	δ_R -Ester (ppm)	$\Delta\delta^{SR}$ (ppm)	$\Delta\delta^{SR}$ (Hz)
15, 15'	7.63	7.73	−0.10	−30
17	6.13	6.21	−0.08	−24
18	3.98	3.80	+0.18	+54
NH'	7.95	7.68	+0.27	+81

In a slightly less polar fraction, we identified a mixture of two compounds **2** and **3** with the same HRESIMS observed for compound **1**. Pure compounds **2** and **3** were obtained by SFC, using a Cyano column. Compound **2** (Figure 2) was isolated as an amorphous white solid, $[\alpha]_D^{25} +61.0^\circ$ (*c* 1.0, MeOH). Its HRESIMS spectrum showed a predominant peak at *m/z* 1136.6924 [M+Na]⁺ corresponding to the molecular formula C₃₁H₃₀⁷⁹Br₃⁸¹Br₃N₄O₁₁ (calc. for C₃₁H₃₀Br₆N₄O₁₁Na: 1136.6849). This isomer of fistularin-3 presented some differences on the ¹H NMR spectrum. The singlet H-5 expected at δ_H 6.55 ppm was not observed, but another one appeared at δ_H 7.56 ppm, a chemical shift in accordance with an aromatic proton. An interesting change was observed for the CH₂-7' observed at δ_H 3.81 ppm as a singlet associated by HSQC with a carbon observed at the low chemical shift δ_C 25.5 ppm. The COSY spectrum (Figure 2) displayed cross-peak correlations between the signals at δ_H 7.56 and 3.81 corresponding to a ⁴*J* coupling suggesting an aromatization together with one of the spiroisoxazoline opening. The second spiroisoxazoline with its diastereotopic protons at δ_H 3.87–3.84/3.22–3.18 was observed. The ¹³C NMR spectrum showed more signals similar to those observed for compound **1**, suggesting its partial modification. The HMBC spectrum showed a key correlation between the protons of the methylene group at δ_H 3.81 and the carbons at δ_C 155.1(C1') and 122.1(C6'). Furthermore, the proton H-5' at δ_H 7.56 was also correlated to C-1', C-6', and to those at δ_C 106.3 (C-4') and 108.9 (C-2'). The COSY spectrum (recorded in acetone-*d*₆) revealed a spin system

including a methylene group CH₂-10 at δ_H 3.78/3.52, followed by an -NH proton at δ_H 7.62 and oxymethine CH-11 at δ_H 4.24, and terminated with two diastereotopic protons CH₂-12 at δ_H 4.02/4.05. The HMBC spectrum displayed key correlations between H-10 and H-7 with the amidic carbonyl C-9 at δ_C 160.4 (Figure 3), which confirmed that the left-hand side of the molecule was retained is an oxazolinic motif like in compound 1. Further significant HMBC correlations were observed between CH₂-12 δ_H 4.02/4.05 and C-13 at δ_C 152.7. Additionally, the COSY spectrum allowed us to identify a second partial structure including the oxymethine H-17 at δ_H 4.92, two diastereotopic protons at δ_H 3.64/3.49, and -NH at δ_H 8.05 ppm. The proton CH-17 at δ_H 4.92 displayed key HMBC corrections with C-15/15' and C-16 at δ_C 131.5 and 143.1, respectively. Furthermore, the methylene groups CH₂-18 at δ_H 3.64/3.49 and CH₂-7' at δ_H 3.85/3.19 exhibited additional HMBC correlations with the quaternary carbon C-9' at δ_C 166.7, which confirmed the planar structure of the compound 2. The stereochemistry of the spiroisoxazoline moiety was determined as 1*R*, 6*S* by its ECD spectrum, which showed characteristic positive Cotton effects at 256 nm ($\Delta\epsilon$ +2.55) and 290 nm ($\Delta\epsilon$ +2.17). Compound 2 was named suberein-1.




Figure 3. Selected COSY and HMBC correlations for suberein-1 (2).

Compound 3 (Figure 4) was a regioisomer of compound 2 ($[\alpha]_D^{25} + 70.7^\circ$ (*c* 1.0, MeOH)). The HRESIMS spectrum showed the predominant peak at m/z 1136.6864 [$M+Na$]⁺, corresponding to a molecular formula C₃₁H₃₀Br₆N₄O₁₁ (calc. for C₃₁H₃₀Br₆N₄O₁₁Na, 1136.6849). The ¹H and ¹³C NMR spectral data (Table 2) were similar to those of compound 2 and suggested the opening of the other spiroisoxazoline moiety. This was confirmed by the key HMBC correlations between the methylene groups CH₂-7 at δ_H 3.84 and CH₂-10 at δ_H 3.78/3.58 with the amidic carbonyl C-9 at δ_C 166.6 (Figure 4). The absolute configuration of the spiroisoxazoline moiety was determined as 1*R*, 6*S* based on positive Cotton effects at 255 nm ($\Delta\epsilon$ +2.33) and 286 nm ($\Delta\epsilon$ +2.19), in its ECD spectrum. Compound 3 was named suberein-2.




Figure 4. Selected COSY and HMBC correlations for suberein-2 (3).

Table 2. NMR spectroscopic data of suberein-1 (2) and suberein-2 (3) in acetone-*d*₆.

Position	Suberein-1 (2) (500 MHz)		Suberein-2 (3) (600 MHz)	
	δ_C , Type	δ_H Mult, (J in Hz)	δ_C , Type	δ_H Mult, (J in Hz)
1	75.2, CH	4.20, s	155.1, C	-
2	113.9, C	-	108.9, C	-
3	148.8, C	-	154.7, C	-
4	122.1, C	-	106.1, C	-
5	132.1, CH	6.53, s	134.7, CH	7.57, s
6	91.9, C	-	122.2, C	-
7	40.1, CH ₂	3.85, d (18.4) 3.19, d (18.4)	25.6, CH ₂	3.84, s
8	155.2, C	-	151.1, C	-
9	160.4, C	-	166.6, C	-
10	43.5, CH ₂	3.78, m 3.52, m	43.6, CH ₂	3.78, m 3.58, m
11	69.8, CH	4.24, m	69.2, CH	4.25, m
12	75.9, CH ₂	4.05, dd (9.0, 5.2) 4.02, dd (9.0, 5.2)	75.6, CH ₂	4.04, dd (9.1, 5.4) 3.99, dd (9.1, 5.4)
13	152.7, C	-	152.5, C	-
14, 14'	118.4, C	-	118.3, C	-
15, 15'	131.5, CH	7.65, s	131.4, CH	7.63, s
16	143.1, C	-	143.2, C	-
17	71.0, CH	4.92, dd (7.7, 4.5)	71.3, CH	4.89, dd (7.7, 4.5)
18	47.7, CH ₂	3.64, m 3.49, m	47.4, CH ₂	3.61, m 3.45, m
1'	155.1, C *	-	75.1, CH	4.18, s
2'	108.9, C	-	113.9, C	-
3'	154.8, C	-	148.7, C	-
4'	106.3, C	-	122.1, C	-
5'	134.9, CH	7.56, s	132.1, CH	6.52, s
6'	122.1, C	-	91.8, C	-
7'	25.7, CH ₂	3.81, s	39.8, CH ₂	3.83, d (18.4) 3.17, d (18.4)
8'	151.2, C	-	155.3, C	-
9'	166.7, C	-	160.4, C	-
OMe	60.2, CH ₃	3.73, s	60.5, CH ₃	3.80, s
OMe'	60.6, CH ₃	3.81, s	60.5, CH ₃	3.72, s
NH	-	7.62, bt (5.7)	-	8.10, bt (6.8)
NH'	-	8.05, bt (6.8)	-	7.74, bt (5.7)
OH-1, OH-1'	-	-	-	-
OH-11	-	-	-	-
OH-17	-	-	-	-

Compounds **4** + **5** were isolated together as an inseparable 1/1 mixture. Their HRES-IMS spectrum exhibited a predominant peak at m/z 1100.6935 $[M+H]^+$ corresponding to a molecular formula $C_{30}H_{28}Br_6N_4O_{11}$ (calc. for $C_{30}H_{29}Br_6N_4O_{11}$, 1100.6872), which indicated 14 a.m.u less than 11-*epi*-fistularin-3 (**1**). The 1H NMR spectrum (Table 3) showed only one methyl group as a singlet at δ_H 3.73 instead of two in 11-*epi*-fistularin-3 (**1**). Indeed, the ^{13}C NMR spectrum disclosed two characteristic resonances at δ_C 183.6 (C-3') assigned to a carbonyl group, and δ_C 75.3 attributed to C-1', which were not recorded for 11-*epi*-fistularin-3 (**1**). The COSY spectrum showed key correlations between the proton at δ_H 5.08 (H-2') and the oxymethine at δ_H 4.41 (H-1'), with a coupling constant $J = 11.4$ Hz. Significant HMBC correlations were observed between the proton H-5' and the carbons at δ_C 75.3 (C-1'), 57.4 (C-2'), 183.6 (C-3'), 122.6 (C-4'), and 91.8 (C-6'). Additionally, the oxymethine H-1' was correlated with C-2' and meanwhile, H-2' was correlated with C-3'. Thus, the structure of **4** was determined as described in Figure 5. The same demethoxylated substructure was observed on its isomer **5** in the left side of the molecule (C-1 to C-6 instead of C-1' to C-6'). The observed NOE correlation between H-2' and one of the H-5' together

with the absence of NOE correlations between H-1' and H2' suggested a *trans* configuration for 4 + 5. Compounds 4 and 5 are named suberein-3 and suberein-4, respectively.




Figure 5. Key COSY, HMBC, and NOE correlations differentiating suberein-3 (4) and suberein-4 (5).

Table 3. NMR spectroscopic data of suberein-3 (4) and suberein-4 (5) (500, 125 MHz, acetone- d_6).

Suberein-3 (4)			Suberein-4 (5)	
Position	δ_C , Type	δ_H Mult, (J in Hz)	δ_C , Type	δ_H Mult, (J in Hz)
1	75.0, CH	4.18, d (6.0)	75.2, CH	4.40, dd (11.4, 6.0)
2	113.9, C	-	57.4, CH	5.09, d (11.4)
3	148.8, C	-	183.6, C	-
4	122.2, C	-	122.6, C	-
5	132.3, CH	6.53, s	149.3, CH	7.62, s
6	91.8, C	-	91.8, C	-
7	40.0, CH ₂	3.82, d (18.4) 3.16, d (18.4)	38.4, CH ₂	3.86, d (18.4) 3.25, d (18.4)
8	155.2, C	-	155.1, C	-
9	160.3, C	-	160.4, C	-
10	43.7, CH ₂	3.78, m 3.52, m	43.7, CH ₂	3.78, m 3.52, m
11	69.9, CH	4.25, m	69.9, CH	4.25, m
12	76.0, CH ₂	4.06, m 4.04, m	76.0, CH ₂	4.06, m 4.04, m
13	152.7, C	-	152.2, C	-
14, 14'	118.4, C	-	118.3, C	-
15, 15'	131.5, CH	7.66, s	131.5, CH	7.67, s
16	143.3, C	-	143.3, C	-
17	71.4, CH	4.91, m 3.62, m 3.48, m	71.4, CH	4.91, m 3.62, m 3.48, m
18	47.6, CH ₂	4.41, dd (11.4, 6.0) 5.08, d (11.4)	47.6, CH ₂	4.20, d (6.0)
1'	75.3, CH	-	75.1, CH	-
2'	57.4, CH	-	113.9, C	-
3'	183.6, C	-	148.7, C	-
4'	122.6, C	-	122.2, C	-
5'	149.4, CH	7.64, s	132.1, CH	6.52, s
6'	91.8, C	-	91.8, C	-
7'	38.5, CH ₂	3.88, d (18.4) 3.29, d (18.4)	40.1, CH ₂	3.86, d (18.4) 3.20, d (18.4)
8'	155.1, C	-	155.2, C	-
9'	160.4, C	-	160.3, C	-
OMe	60.2, CH ₃	3.73, s	-	-
OMe'	-	-	60.2, CH ₃	3.73, s
NH	-	7.63, m	-	7.63, m
NH'	-	7.67, m	-	7.67, m
OH-1	-	5.41, d (6.0)	-	5.96, d (6.0)
OH-1'	-	5.97, d (6.0)	-	5.41, d (6.0)
OH-11	-	4.44, m	-	4.44, m
OH-17	-	5.01, m	-	5.01, m

As for **4 + 5**, the following compounds **6 + 7** were also isolated together as an inseparable in 1/1 mixture. Their molecular formulas were established as $C_{30}H_{28}Br_6N_4O_{11}$ from their positive HRESIMS spectrum with a predominant peak at m/z 1100.6935 $[M+H]^+$, (calc. for $C_{30}H_{29}^{79}Br_3^{81}Br_3N_4O_{11}$, 1100.6872). Their 1H NMR spectrum (Table 4) showed strong similarities with their stereoisomers **4 + 5**, but the main difference appeared in the chemical shift of H-5/H-5', H-1/H-1' and H-2/H-2'. The coupling constant between H-1/H-1' and H-2/H-2' was close very weak (br s) suggesting a *cis* configuration, which was further confirmed by the NOE correlations. Therefore, the structure of **6** and **7** were assigned as described in Figure 6 and named suberein-6 and suberein-7, respectively.

Table 4. NMR spectroscopic data of suberein-5 (**6**) and suberein-6 (**7**) (500, 125 MHz, acetone- d_6).

Position	Suberein-5 (6)		Suberein-6 (7)	
	δ_C , Type	δ_H Mult, (J in Hz)	δ_C , Type	δ_H Mult, (J in Hz)
1	75.2, CH	4.18, br s	73.1, CH	4.57, br s
2	113.9, C	-	54.8, CH	5.27, br s
3	148.8, C	-	183.6, C	-
4	122.2, C	-	122.1, C	-
5	132.4, CH	6.53, s	146.4, CH	7.47, s
6	91.8, C	-	90.8, C	-
7	40.1, CH ₂	3.82, d (18.4) 3.16, d (18.4)	41.5, CH ₂	3.88, d (18.4) 3.35, d (18.4)
8	155.2, C	-	155.1, C	-
9	160.4, C	-	160.5, C	-
10	43.6, CH ₂	3.78, m 3.52, m	43.6, CH ₂	3.78, m 3.52, m
11	69.9, CH	4.25, m	69.9, CH	4.25, m
12	76.0, CH ₂	4.06, m 4.04, m	76.0, CH ₂	4.06, m 4.04, m
13	152.7, C	-	152.7, C	-
14, 14'	118.4, C	-	118.4, C	-
15, 15'	131.4, CH	7.67, s	131.3, CH	7.66, s
16	143.3, C	-	143.3, C	-
17	71.4, CH	4.91, m 3.62, m	71.4, CH	4.91, m 3.62, m
18	47.6, CH ₂	3.48, m	47.6, CH ₂	3.48, m
1'	73.2, CH	4.57, br s	75.3, CH	4.19, br s
2'	54.8, CH	5.27, br s	113.9, C	-
3'	183.6, C	-	148.8, C	-
4'	122.1, C	-	122.2, C	-
5'	146.4, CH	7.49, s	132.3, CH	6.52, s
6'	90.8, C	-	91.8, C	-
7'	41.5, CH ₂	3.91, d (18.4) 3.39, d (18.4)	40.1, CH ₂	3.86, d (18.4) 3.20, d (18.4)
8'	155.1, C	-	155.2, C	-
9'	160.5, C	-	160.4, C	-
OMe	60.2, CH ₃	3.73, s	-	-
OMe'	-	-	60.2, CH ₃	3.73, s
NH	-	7.63, br t (5.0)	-	7.66, br t (5.0)
NH'	-	7.66, br t (5.0)	-	7.73, br t (5.0)
OH-1	-	5.45, br s	-	5.95, br s
OH-1'	-	5.95, br s	-	5.45, br s
OH-11	-	4.47, br s	-	4.47, br s
OH-17	-	5.04, br s	-	5.04, br s




Figure 6. Key COSY and HMBC correlations of suberein-5 (6) and suberein-6 (7).

It should be noted that due to the keto-enolic equilibrium, carbons C-2 and C-2' in both mixtures 4 + 5 and 6 + 7 epimerize within two days in solution into a mixture of 4/5/6/7: 1/1/1/1. Their purification just allowed their characterisation as mixtures of the structures of the *cis* stereoisomers on the one hand and of the *trans* stereoisomers on the other hand.

Compound 8 was isolated as an amorphous powder ($[\alpha]_D^{25} + 149.5^\circ$ (*c* 0.5, MeOH)). Its HRESIMS showed an isotopic cluster indicating six bromines with a principal peak at m/z 1110.6661 $[M-H]^-$ corresponding to a molecular formula $C_{31}H_{28}Br_6N_4O_{11}$ (calc. for $C_{31}H_{27}Br_6N_4O_{11}$, 1110.6715). Its 1H NMR spectrum (Table 2) showed the characteristic signals of the fistularin-3 with some modifications, including the presence of a doublet at δ_H 4.87 (H-18) together with the absence of the H-17 signal observed for fistularin-3 at δ_H 4.90. The chemical shift of the aromatic protons (H-15/15') was observed at δ_H 8.28. The ^{13}C NMR spectrum (Table 2) showed a quaternary carbon at δ_C 192.2, characteristic for a carbonyl group. The HMBC spectrum displayed significant correlations between H₂-18 (δ_H 4.87), H-15/15' (δ_H 8.28), and the non-protonated carbon at δ_C 192.2, thus assigning the carbonyl group to C-17. Further key HMBC correlations were consistent with the backbone of fistularin-3. Thus, the structure was depicted as 17-oxo-11-*epi*-fistularin-3 for compound 8 and named suberein-7 (Figure 7), a new member of the bromotyrosine-derived compounds.




Figure 7. Key HMBC correlations for suberein-7 (8).

Compound 9 ($[\alpha]_D^{25} + 84.0^\circ$ (*c* 0.2, MeOH)) showed in its HRESIMS an isotopic cluster of peaks indicating a tetrabrominated compound with a principal peak at m/z 761.8695 $[M+H]^+$ corresponding to the molecular formula $C_{23}H_{26}Br_4N_3O_6$ (calc. for $C_{23}H_{28}Br_4N_3O_6$, 761.8671). The 1H NMR spectrum (Table 5) disclosed characteristic signals with similar chemical shifts to those reported for the right-hand side of *epi*-fistularin-3 (1). The COSY spectrum allowed the identification of additional spin system including an oxymethylene group (CH₂-16) at δ_H 4.07 based on its chemical shift and CH₂ group at δ_H 2.11 (CH₂-17), and terminated with an azomethylene group (CH₂-18) at δ_H 2.87. A singlet at δ_H 2.47 integrated for six protons was assigned to the *N,N*-dimethyl terminus (CH₃-19/20). The HMBC spectrum displayed key correlations between the oxymethylene group at δ_H 4.07 (CH₂-16) and the quaternary carbon C-15 at δ_C 152.1, linking this partial structure to the tetrasubstituted phenyl ring. Furthermore, the signal corresponding to the *N,N*-dimethyl functionality (δ_H 2.47, CH₃-19/20) displayed HMBC correlation with the carbon C-18 at δ_C

56.0. The other HMBC correlations were consistent with the proposed structure for **9** and named suberein-8 (Figure 8).

Table 5. Spectroscopic data of compounds **8** (600 MHz, acetone- d_6) and **9** (500, MeOH- d_4).

Suberein-7 (8) (600 MHz, Acetone- d_6)			Suberein-8 (9) (500, MHz, MeOH- d_4)		
Position	δ_C , Type	δ_H Mult, (J in Hz)	Position	δ_C , Type	δ_H Mult, (J in Hz)
1	75.2, CH	4.19, s	1	74.2, CH	4.09, s
2	113.9, C	-	2	112.6, C	-
3	148.7, C	-	3	147.9, C	-
4	122.1, C	-	4	121.5, C	-
5	132.3, CH	6.53, s	5	130.7, CH	6.41, s
6	91.8, C	-	6	91.1, C	-
7	40.1, CH ₂	3.86, d (18.4) 3.22, d (18.4)	7	38.3, CH ₂	3.75, d (18.0) 3.06, d (18.0)
8	154.8, C	-	8	153.0, C	-
9	160.6, C	-	9	160.8, C	-
10	43.5, CH ₂	3.78, m 3.53, m	10	47.3, CH ₂	3.74, m 3.40, m
11	69.9, CH	4.29, m	11	70.1, CH ₂	4.76, dd (7.2, 4.7)
12	76.3, CH ₂	4.16, m	12	142.5, C	-
13	158.0, C	-	13, 13'	130.2, CH	7.62, s
14, 14'	119.2, C	-	14, 14'	117.6, C	-
15, 15'	133.6, CH	8.28, s	15	152.1, C	-
16	134.3, C	-	16	71.8, CH ₂	4.07, t (6.5)
17	192.2, C	-	17	26.5, CH ₂	2.11, m
18	45.9, CH ₂	4.87, d (5.2)	18	56.0, CH ₂	2.87, m
1'	75.2, CH	4.23, s	19	43.8 CH ₃	2.47, s
2'	113.9, C	-	20	43.8, CH	2.47, s
3'	148.7, C	-	OMe	59.0, CH ₃	3.73, s
4'	122.1, C	-			
5'	132.3, CH	6.57, s			
6'	92.0, C	-			
7'	39.9, CH ₂	3.86, d (18.4) 3.19, d (18.4)			
8'	155.2, C	-			
9'	160.2, C	-			
OMe	60.2, CH ₃	3.73, s			
OMe'	60.2, CH ₃	3.73, s			
NH	-	7.67, bt (6.2)			
NH'	-	7.91, bt (5.2)			
OH-1, OH-1'	-	5.47, br s			
OH-11	-	4.58, br s			
OH-17	-	-			




Figure 8. Key COSY and HMBC correlations for suberein-8 (**9**).

Compound **10** ($[\alpha]_D^{25} + 71.0^\circ$ (c 0.3, MeOH)) showed in its negative HRESIMS a characteristic isotopic cluster of a hexabrominated compound with a predominant peak at m/z 1096.6923 $[M-H]^-$ corresponding to the molecular formula $C_{31}H_{30}Br_6N_4O_{10}$ (calc. for $C_{31}H_{29}Br_6N_4O_{10}$, 1096.6923). Its 1H NMR spectral pattern was identical to the one of

17-deoxyfistularin-3 [21]. However, the absolute configuration of C-11 was not determined. As for compound *epi*-fistularin (**1**) described above, placing 17-deoxyfistularin-3 (**10**) after hydrolysis in aqueous trifluoroacetic acid to obtain the 1,2-aminopropanediol and further Marfey's derivatization and comparison with *R* and *S* 1,2-aminopropanediol standards, we found that the absolute configuration of C-11 was *R*. Thus, compound **10** was assigned as a 17-deoxy-11(*R*)-*epi*-fistularin-3 (Figure 9).




Figure 9. Key HMBC correlations of 17-deoxy-11(*R*)-*epi*-fistularin-3 (**10**).

The presence of agelorins and compounds **2–8** with 11-*epi*-fistularin (**1**) in our sponge brings us to the question of which one the precursor is, and if degradation processes can take place during purification. This is interesting because all the reactions involved are simple and can be imagined without any particular catalysis. Hydrolysis and simple oxidation of the benzylic alcohol into ketone can take place spontaneously. The presence of water, oxygen, and the variation of the acid–base conditions are sufficient. As noted above, such transformations were previously observed for agelorins A–B (**11–12**) which were isolated separately with a smaller retention time [4,29]. Rogers et al. identified a mixture of these two products in a sample of *epi*-fistularin-3 (**1**) after storing for several years at $-20\text{ }^{\circ}\text{C}$ [29]. When *epi*-fistularin-3 is heated in acidic conditions, several degradation compounds appeared. We then decided to manage the degradation process of *epi*-fistularin-3 (**1**) in a less drastic conditions by dissolving it in a mixture of acetonitrile/water (+0.1% HCOOH) 1/1 and stirring at room temperature for two weeks. The reaction mixture was then dried under vacuum and chromatographed. In addition to the formation of agelorin A and agelorin B, we identified compounds **2–7** as well. This result raises the interesting question as to whether these compounds are natural or simply degradation derivatives of 11-*epi*-fistularin-3 (**1**).

3. Biological Activities

3.1. Antibacterial Activity Inhibition

Minimum inhibitory concentration (MIC values) results are presented in Table 6. Compounds were tested against a panel of bacterial strains commonly used for assessment of their anti-biofilm properties [34]. None of the compounds tested displayed antibacterial activity (at the concentrations tested) against all the panel of bacteria tested (four marine bacteria): *Vibrio natriegens*, *Shewanella putrefaciens*, *Pseudoalteromonas elyakovii*, *Polaribacter irgensii*; and two terrestrial bacteria: *Staphylococcus aureus* and *Pseudomonas aeruginosa*. Moreover, among all the tested compounds, no activity was observed (at the tested concentrations) for 11-*epi*-fistularin-3 (**1**), compounds **4** and **5**, 11-hydroxyaerotherionin (**15**), and aplysinamin-1 (**17**).

The most active molecule was compound **3**, which displayed an MIC value of $0.01\text{ }\mu\text{g/mL}$ (the lowest concentration tested) against *V. aesturianus* and *E. coli*. These results are of great importance as new inhibitors against these strains are sought-after actively by scientists, and indeed not only for antifouling purposes. *E. coli* is a common inhabitant of the human gut microbiota and commonly causes nosocomial infection, urinary tract infections, neonate meningitis, and bacteria-related diarrhea. Resistance to antimicrobial agents (e.g., broad-spectrum penicillin and trimethoprim or third generation cephalosporin and nitrofurantoin) in *E. coli* has been reported worldwide and has an increasing impact on available therapeutic options [35]. There is an urgent need for new compounds inhibiting the growth of *E. coli*. The inhibition of *V. aesturianus* is of high importance as well as this bacterial strain is involved in surface colonization, but it is as well a known pathogen of

the commercial oyster *Crassostrea gigas* [36–38]. Compounds 2–4 could possibly be used in aquaculture for the prevention of diseases. The oyster industry has grown to be very important in many regions of the world contributing substantially to social and economic activity in coastal zones. Abnormal mortality events due to outbreaks of *V. aesturianus* have been reported increasingly since 2008, leading to very high levels of mortality which were sudden and severe (up to 100%), and affected essentially spats (oysters less than one year old) and juveniles (12- to 18-month-old oysters). Massive mortality outbreaks resulted in a shortage in supplies of the shellfish over the next years [39].

Table 6. Biological activity of *epi*-fistularin-3 (1) and related compounds.

Compounds	<i>Vibrio</i>	<i>Roseobacter</i>	<i>Halomonas</i>	<i>Escherichia</i>	Acetylcholinesterase
	<i>aesturianus</i>	<i>littoralis</i>	<i>aquamarina</i>	<i>coli</i>	
	MIC μ M	MIC μ M	MIC μ M	MIC μ M	IC ₅₀ μ M
<i>epi</i> -fistularin-3 (1)	>1	>1	>1	>1	>10
suberein-1 (2)	0.01	1	>1	>1	>10
suberein-2 (3)	0.01	>1	>1	0.01	>10
17-oxo-11- <i>epi</i> -fistularin-3 (8)	0.01	>1	>1	>1	>10
17-deoxy-11- <i>epi</i> -fistularin-3 (10)	>1	>1	0,01	>1	>10
agelorin A (11)	0.1	0.1	0.1	nt	0.19 \pm 0.2
agelorin B (12)	>1	>1	>1	>1	nt
11-deoxyfistularin-3 (13)	>1	>1	0,01	>1	>10
11,17-dideoxyfistularin (14)	>1	>1	0,01	>1	10 \pm 0.3
11-hydroxyaerolithionin (15)	>1	>1	0,01	>1	10 \pm 0.3

It is worth mentioning that the mono- or di-deoxyfistularins (11-deoxyfistularin-3 (13), 11,17-dideoxyfistularin-3 (15)) displayed MIC values of 0.01 μ g/mL (the lowest concentration tested) specifically toward *Halomonas aquamarina*. The discovery of *H. aquamarina* inhibitors is also of great interest since this strain is involved in both marine biofilm formation [40,41] and pathogenicity towards lobster *Homarus americanus*, an important species in aquaculture [42]. *Halomonas aquamarina* also poses a threat as a potential invasive species because it can lead to potential invasion when transported on biofilms inside ballast water tanks [43].

Molecules with targeted activities are of major interest because they make it possible to fight specifically against targeted bacteria without altering non-targeted organisms. This significantly slows down the development of resistance.

3.2. Acetylcholinesterase Activity Inhibition

The activity of these compounds was also evaluated on acetylcholinesterase, which is responsible in terrestrial invertebrates for various primordial biosynthetic pathways, the inhibition of which can be lethal for insect species and thus represents a great phytosanitary interest [44,45], and also might be a toxicity indicator in the marine environment, especially in bivalves [46].

The involvement of neurotransmission inhibition through acetylcholinesterase inhibition has been shown in a settlement of cyprid larvae of barnacles [47,48]. Agelorin A (12) displayed a better activity than the reference compound Galantamine used as a control for the bioassay (IC₅₀ = 0.7 \pm 0.1 μ M). The acetylcholinesterase inhibition of bromotyrosine derivatives enhances their interest as efficient antifouling natural products especially in their natural environment as a mode of chemical defense.

3.3. DNMT1 Activity Inhibition

Aberrant DNA methylation is a hallmark of cancer cells, and the enzyme DNA methyltransferase 1 (DNMT1) represents a recognized target in cancer treatment. As a continuation of our previously demonstrated potential of 11-*epi*-fistularin (1) to bind DNMT1 and reduce its activity [28], and that of isofistularin-3 extracted from the sponge

Aplysina aerophoba, and its ability to inhibit DNMT1 leading to DNA demethylation in leukemia cells [49], we also investigated the capacity of our compounds **2**, **3**, **13**, and **14** to modulate the activity of DNMT1 (Figure 10). Results were compared to bromotyrosine compounds psammaplysene D (**21**), F (**22**), and G (**23**) (SI Figure S0), previously isolated from another sponge species in our group, *Suberea ianthelliformis* [19].




Figure 10. In vitro DNMT1 activity inhibition assays with 11-*epi*-fistularin (**1**), compounds (**2**, **3**, **13**, and **14**), and psammaplysene D (**21**), F (**22**), and G (**23**) (all compounds are used at 50 μ M). The graph corresponds to the mean \pm SD of three independent experiments. * $p < 0.05$; ** $p < 0.01$ (paired repeated measure one-way Anova with Dunnet's multiple comparison test).

In line with our previous results, compound **1** reduced DNMT1 activity to around 70% of control values and compound **14** also provided a statistically significant decrease.

In summary of this manuscript, the chemical examination of the Pacific marine sponge *Suberea clavata* led to the isolation and identification of twenty structurally diverse brominated tyrosine metabolites, of which eight are new congeners, subereins-1–8 (**2–9**), along with two major co-isolated known products 11-*epi*-fistularin-3 (**1**) and 17-deoxyfistularin-3 (**10**). A combination of chemical modifications, Mosher's technology, and ECD spectroscopy allowed the complete assignment of the absolute configurations of the new compounds on one hand, and the assignment of the stereogenic centers C-11/17 of the known congeners (11*R*,17*S*) 11-*epi*-fistularin-3 (**1**) and 17-deoxyfistularin-3 (**10**) for the first time on the other hand.

This solves the problem of the absolute configuration of the C-17 of 11-*epi*-fistularin-3 (**1**), which has remained undetermined since 1993 [4]. Whereas this metabolite is predominant in several sponges and presents interesting biological activities, the easily observed transformation of the major compound 11-*epi*-fistularin-3 (**1**) into subereins 1–6 (**2–7**) rise the question of artifacts of extraction. We believe that all compounds are also present in the sponge since they are present in the crud extract of the sponge. This does not exclude their partial formation during chromatographic purifications. The isolated compounds **3**, **13**, and **15** displayed antimicrobial inhibition; **12** displayed acetylcholinesterase inhibition; and **1** and **14** inhibited DNMT1.

4. Materials and Methods

4.1. General Experimental Procedure

Optical rotations $[\alpha]_D$ were measured at 25 $^{\circ}$ C on a Jasco P-1010 polarimeter (JASCO, Lisses, France). Electronic circular dichroism (ECD) experiments were performed at 25 $^{\circ}$ C on a JASCO J-810 spectropolarimeter (JASCO, Lisses, France). IR spectra were recorded on a Perkin Elmer BX FT-IR spectrometer (Perkin Elmer, Villebon-sur-Yvette, France). The NMR spectra were recorded on a Bruker 300 MHz instrument (Avance 300), a Bruker

500 MHz instrument (Avance 500,) and a Bruker DRX 600 MHz with a 5 mm or 1.7 mm triple resonance (HCN) probe (Bruker, Wissembourg, France). The chemical shifts are reported in ppm relative to the residual signal solvent (MeOH- d_4 : δ_H 3.31; δ_C 49.15; DMF- d_7 : δ_H 8.03, 2.92, 2.75; δ_C 163.15, 34.89, 29.76; acetone- d_6 : δ_H 2.05; δ_C 206.68, 29.92). High-resolution mass spectra were obtained with a hybrid linear trap/orbitrap mass spectrometer (LTQ-orbitrap, Thermofisher, Illkirch, France) in electrospray ionization mode by direct infusion of the purified compounds. MPLC was performed using a Combiflash-Companion apparatus (Serlabo Technologies, Entraigues-sur-la-Sorgue, France) and a prepacked C₁₈ Versapak cartridge. Preparative HPLC purifications were performed on an autoprep system (Waters 600 controller and Waters 600 pump with a Waters 996 photodiode array detector (Waters France, Guyancourt, France)), equipped with a Waters Atlantis T3 (19 × 150 mm, 5 μ m) column, and a Waters Sunfire C₁₈ (19 × 150 mm, 5 μ m) column or a X-bridge RP-18 (19 × 150 mm, 5 μ m) column. SFC purifications were performed on a Thar Waters SFC Investigator II with a Waters 2998 photodiode array detector, equipped with a SFC 2-Ethyl-pyridine (10 × 250 mm, 6 μ m) column or a Thar Cyano (10 × 250, 6 μ m) column. Analytical UHPLC was performed on UPLC Waters Acquity with PDA, DEDL, and TQD, using a HSS C₁₈ (2.1 × 50 mm, 1.8 μ m) column. All other chemicals and solvents were purchased from SDS (France).

4.2. Biological Material

The sponge was collected by hand using SCUBA in the Solomon Islands, Russell Group, during the sampling cruise BSMS-1 [50] aboard the R/V Alis, off the coast of Lologhan Island (30 June 2004, 9°06.658' S; 159°21.664' E) between 6 and 12 m deep. A voucher sample is deposited at the Queensland Museum (Brisbane, Australia) under the access number G322641 and was identified by Dr. J. N. A. Hooper as *Suberea clavata*. The sponge was deep frozen on board until work up. It was then grounded, freeze-dried, and extracted.

4.3. Isolation and Spectroscopic Data

4.3.1. Isolation

The lyophilized sponge *Suberea clavata* (200 g) was extracted at room temperature with MeOH/DCM (1/1) to give 57.8 g of dried extract. The crude extract was submitted to *n*-butanol/H₂O partition to obtain a desalted butanol extract (30 g). A portion (25 g) of the later extract was submitted to reversed-phase C₁₈ SPE (50 μ m, 65 Å, Phenomenex Septra) and eluted with a gradient H₂O/MeOH (100/0 to 0/100) and MeOH/DCM (100/0 to 0/100) to give six fractions f1 to f6. The fraction f4 (10 g) was submitted to reversed-phase HPLC (Waters Sunfire C₁₈ column, H₂O + 0.1% HCOOH/CH₃CN + 0.1% HCOOH: 85/15 to 0/100 in 40 min) yielding 13 subfractions, F1 to F13. The sub-fraction F1 afforded pure aerophobin-2 (**16**) (140 mg, R_T = 10 min).

Fraction F6 only contained 11-*epi*-fistularin-3 (**1**) (2.7 g, R_T = 21.8 min) and F9 pure 11,17-dideoxyfistularin-3 (**14**) (220 mg, R_T = 25.6 min).

Fraction F7 was purified by SFC (ethylpyridine column, CO₂/MeOH (75/25), isocratic condition) and yielded 17-deoxy-*epi*-fistularin-3 (**10**) (8 mg, R_T = 12.0 min), 11-deoxyfistularin-3 (**14**) (36 mg, R_T = 11.5 min), and 17-oxo-11-*epi*-fistularin-3 (**8**) (9 mg, R_T = 14.1 min).

Fraction F8 was purified by SFC (cyano column, CO₂/iPrOH (75/25), isocratic condition) to yield 11-*epi*-fistularin-3 (**1**), suberein-1 (**2**) (10 mg, R_T = 11.8 min), and suberein-1 (**3**) (10 mg, R_T = 13.0 min).

Fraction F5 was submitted to reversed-phase HPLC (Waters Sunfire C₁₈, H₂O + 0.1% HCOOH/CH₃CN + 0.1% HCOOH, 85/15 to 25/75 in 25 min). Agelorin A (**11**) (3 mg, R_T = 19.6) and B (**12**) (3 mg, R_T = 20.1), 11-hydroxyaerotionin (**15**) (2 mg, R_T = 22.2 min), as well as a mixture of **4** + **5** (5 mg, R_T = 20.9 min) and a mixture of **6** + **7** (5 mg, R_T = 21.2 min), were obtained.

Fraction F1 (1.5 g) was purified by MPLC (Versapak C₁₈ silica-gel cartridge (23 × 110 mm); H₂O + 0.1% HCOOH/MeOH+0.1% HCOOH, 100/0 to 0/100, in 35 min). It yielded eight subfractions F'1 to F'8. Pseudoceralidinone A (**20**) (5 mg, R_T = 3.5 min) was obtained from F'1. Fraction F'7 was submitted to reversed-phase HPLC (Atlantis T3 C₁₈, H₂O + 0.1% HCOOH/CH₃CN + 0.1% HCOOH, 100/0 to 75/25 in 7 min, 75/25 to 50/50 in 18 min) to afford aplysinamisin-1 (**17**) (15 mg, R_T = 10.5 min), subereaphenol K (**19**) (4 mg, R_T = 11.1 min), and 7R, 11S [3,5-dibromo-4-[(2-oxo-5-oxazolidinyl)]methoxyphenyl]-2-oxazolidinone (**18**) (17 mg, R_T = 12.5 min). Fraction F'8 afforded suberein-8 (**9**) (3 mg, R_T = 24.0 min) by reversed-phase HPLC purification using an Xbridge C₁₈ column (pH 10.5, H₂O + 0.15% NH₄OH)/ CH₃CN + 0.15% NH₄OH, 90/10 to 0/100 in 35 min).

4.3.2. Spectroscopic Data and Absolute Configurations Determination

17*S*-*epi*-fistularin-3 (**1**): yellowish amorphous solid (3 g); [α]_D²⁵ + 148.0° (c 1.0, MeOH); [α]_D²⁵ + 169.0 (c 0.2, acetone); ECD (0.15 mM, MeOH) λ_{max} (Δε) 253 (+7.5), 285 (+8.0); ¹H NMR (500 MHz, acetone-*d*₆): δ_H ppm 7.67 (m, 1H, NH'), 7.66 (s, 2H, H-15, H-15'), 7.62 (m, 1H, NH), 6.53 (d, 2H, H-5, H-5'), 5.41 (d, *J* = 8.0 Hz, 2H, OH-1, OH-1'), 5.00 (d, *J* = 4.3 Hz, 1H, OH-17), 4.90 (dd, *J* = 7.7, 5.5, 4.3 Hz, 1H, H-17), 4.44 (d, *J* = 5.3 Hz, 1H, OH-11), 4.25 (m, 1H, H-11), 4.18 (dd, *J* = 8.0 Hz, 2H, H-1, H-1'), 4.04 (m, 2H, H-12), 3.85 (d, *J* = 18.0 Hz, 1H, H-7a), 3.82 (d, *J* = 18.0 Hz, 1H, H-7a'), 3.80 (m, 1H, H-10a), 3.73 (s, 6H, OCH₃, OCH₃'), 3.63 (m, 1H, H-18a), 3.54 (m, 1H, H-10b), 3.49 (m, 1H, H-18b), 3.19 (d, *J* = 18.0 Hz, 1H, H-7b), 3.16 (d, *J* = 18.0 Hz, 1H, H-7b'); ¹³C NMR (125 MHz, acetone-*d*₆): δ_C ppm 160.5 (C-9, C-9'), 155.2 (C-8'), 155.1 (C-8), 152.7 (C-13), 148.8 (C-3, C-3'), 143.3 (C-16), 132.4 (C-5'), 132.3 (C-5), 131.5 (C-15, C-15'), 122.1 (C-4, C-4'), 118.4 (C-14, C14'), 113.9 (C-2'), 113.8 (C-2), 91.8 (C-6, C-6'), 75.9 (C-12), 75.2 (C-1, C-1'), 71.0 (C-17), 69.9 (C-11), 60.2 (OCH₃, OCH₃'), 47.7 (C-18), 43.6 (C-10), 40.0 (C-7, C-7'); HRESIMS *m/z* 1136.6934 [M+Na]⁺ (calc. for C₃₁H₂₉Br₆N₄O₁₁Na, 1136.6847).

Determination of the C-17 Configuration for 11-*epi*-fistularin-3 (**1**)

To a stirred solution of compound **1** (20 mg, 0.018 mmol) and anhydrous Pyridine (15 μL, 0.18 mmol, 10 equiv.) in anhydrous DCM (270 μL, [1] = 0.066 M) at room temperature, R(-)-MTPA-Cl (34 μL, 0.18 mmol, 10 equiv.) and DMAP (0.5 mg) were added. The reaction progress was monitored by thin-layer chromatography (TLC) on silica gel (95:5 DCM/MeOH). After 3 h, compound **1** was totally consumed. The reaction mixture was quenched by the addition of water and EtOAc. The aqueous layer was extracted with two additional portions of EtOAc, and the combined organic layers were dried on MgSO₄, filtered, and concentrated in vacuo. The crude product mixture was purified by reversed-phase HPLC (Sunfire C₁₈, 10 × 150 mm, 5 μm; eluting with H₂O/acetonitrile (98/2 to 0/100 in 25 min, R_T = 22.3 min.) to give the *S*-MTPA-*epi*-fistularin-3 ester (2.6 mg, 11% yield) as a white solid: ¹H NMR (300 MHz, acetone-*d*₆): δ_H 7.95 (m, 1H, NH'), 7.63 (m, 3H, NH', H-15, H-15'), 7.46 (m, 4H, MTPA), 7.40 (m, 1H, MTPA), 6.52 (dd, *J* = 9, 0.7 Hz, 2H, H-5, H5'), 6.13 (dd, *J* = 8.5, 4.0 Hz, 1H, H-17), 5.42 (m, 2H, OH-1, OH-1'), 4.48 (m, 1H, OH-11), 4.25 (m, 1H, H-11), 4.18 (m, 2H, H-1, H-1'), 4.08 (m, 2H, H-12), 3.98 (m, 2H, H-18), 3.88–3.82 (d, *J* = 18 Hz, 1H, H-7), 3.86–3.80 (d, *J* = 18 Hz, 1H, H-7'), 3.82 (m, 1H, H-10a), 3.73 (d, 6H, 3-OCH₃, 3'-OCH₃), 3.62 (m, 3H, MTPA-OCH₃), 3.55 (m, 1H, H-10b), 3.23–3.17 (d, *J* = 18 Hz, 1H, H-7), 3.19–3.13 (d, *J* = 18 Hz, 1H, H-7'); HRESIMS *m/z* 1352.7357 [M+Na]⁺, (calc. for C₄₁H₃₇⁷⁹Br₃⁸¹Br₃F₃N₄O₁₃Na, 1352.7246).

To a stirred solution of compound **1** (20 mg, 0.018 mmol) and anhydrous Pyridine (15 mL, 0.18 mmol, 10 equiv.) in anhydrous DCM (270 μL, (1) = 0.066 M) at room temperature, *S*(+)-MTPA-Cl (34 μL, 0.18 mmol, 10 equiv.) and DMAP (0.5 mg) were added. The reaction progress was monitored by thin-layer chromatography (TLC) on silica gel (95:5 DCM/MeOH). After 4 h, compound **1** was totally consumed. The reaction mixture was quenched by the addition of water and EtOAc. The aqueous layer was extracted with two additional portions of EtOAc, and the combined organic layers were dried on MgSO₄, filtered, and concentrated in vacuo. The crude product mixture was purified by reversed-

phase HPLC (Sunfire C₁₈, 10 × 150 mm, 5 μm; eluting with H₂O/acetonitrile (98/2 to 0/100 in 25 min, R_T = 21.9 min.)) to give the *R*-MTPA-*epi*-fistularin-3 ester (3.2 mg, 13% yield) as a white solid: ¹H NMR (300 MHz, acetone-*d*₆): δ_H 7.73 (s, 2H, H-15, H15'), 7.68 (m, 2H, NH, NH'), 7.48 (m, 4H, MTPA), 7.30 (m, 1H, MTPA), 6.52 (dd, *J* = 11, 0.9 Hz, 2H, H-5, H5'), 6.21 (dd, *J* = 8, 5 Hz, 1H, H-17), 5.43 (dd, *J* = 8.5, 3.0 Hz, 2H, OH-1, OH-1'), 4.49 (m, 1H, OH-11), 4.26 (m, 1H, H-11), 4.17 (m, 2H, H-1, H-1'), 4.09 (m, 2H, H-12), 3.88–3.83 (d, *J* = 18.3 Hz, 1H, H-7), 3.82–3.77 (d, *J* = 18.3 Hz, 1H, H-7'), 3.80 (m, 1H, H-18), 3.78 (m, 1H, H-10a), 3.73 (d, 6H, 3-OCH₃, 3'-OCH₃), 3.60 (m, 1H, H-10b), 3.50 (s, 3H, MTPA-OCH₃), 3.23–3.16 (d, *J* = 18.5 Hz, 1H, H-7), 3.12–3.06 (d, *J* = 18.5 Hz, 1H, H-7'); HRESIMS *m/z* 1352.7282 [M+Na]⁺ (calc. for C₄₁H₃₇⁷⁹Br₃⁸¹Br₃F₃N₄O₁₃Na, 1352.7246).

Suberein-1 (2): colourless amorphous solid (10 mg); [α]_D²⁵ + 61.0 (*c* 1.0, MeOH); [α]_D²⁵ + 32.5 (*c* 0.2, acetone); UV (MeOH) λ_{max} (ε) 208 (38200), 286 (10100) nm; ECD (0.15 mM, MeOH) λ_{max} (Δε) 214 (−2.79), 256 (2.55), 290 (2.17) nm; IR ν_{max} 3380, 2990, 2900, 1655, 1630, 1545, 1460, 1400, 1255 cm^{−1}; ¹H and ¹³C NMR data, Table 2; HRESIMS *m/z* 1136.6924 [M+Na]⁺ (calc. for C₃₁H₃₀Br₆N₄O₁₁Na, 1136.6849).

Suberein-2 (3): colourless amorphous solid (10 mg); [α]_D²⁵ +70.7 (*c* 1.0, MeOH); [α]_D²⁵ + 32.0 (*c* 0.2, acetone); UV (MeOH) λ_{max} (ε) 208 (38200), 286 (10100) nm; ECD (0.15 mM, MeOH) λ_{max} (Δε) 215 (−1.73), 255 (2.33), 286 (2.19) nm; IR ν_{max} 3360, 2985, 2900, 1655, 1545, 1460, 1415, 1260 cm^{−1}; ¹H and ¹³C NMR data, Table 2; HRESIMS *m/z* 1136.6864 [M+Na]⁺ (calc. for C₃₁H₃₀Br₆N₄O₁₁Na, 1136.6849).

Suberein-3 and suberein-4 (4 and 5): amorphous off-white powder (5 mg); UV (MeOH) λ_{max} (ε) 210 (22500), 232 (7800), 260 (5100) nm; ¹H and ¹³C NMR data, Table 3; HRESIMS *m/z* 1100.6935 [M+H]⁺ (calc. for C₃₀H₂₉Br₆N₄O₁₁, 1100.6872)

Suberein-5 and Suberein-6 (6 and 7): amorphous off-white powder (5 mg); UV (MeOH) λ_{max} (ε) 210 (22500), 232 (7800), 260 (5000) nm; ¹H and ¹³C NMR data, Table 4; HRESIMS *m/z* 1100.6935 [M+H]⁺ (calc. for C₃₀H₂₉Br₆N₄O₁₁, 1100.6872).

Suberein-7 (8): yellow amorphous solid (9 mg); [α]_D²⁵ +149.5 (*c* 0.5, MeOH); [α]_D²⁵ + 14.5 (*c* 0.2, acetone); UV (MeOH) λ_{max} (ε) 210 (29500), 235 (15800), 283 (8800) nm; ECD (0.15 mM, MeOH) λ_{max} (Δε) 253 (7.5), 285 (8.0) nm; IR ν_{max} 3380, 2930, 1670, 1580, 1540, 1270 cm^{−1}; ¹H and ¹³C NMR data, Table 2; HRESIMS *m/z* 1110.6661 [M−H][−] (calc. for C₃₁H₂₇Br₆N₄O₁₁, 1110.6715).

Suberein-8 (9): yellow amorphous solid (3 mg); [α]_D²⁵ +84.0 (*c* 0.2, MeOH); UV (MeOH) λ_{max} (ε) 208 (27800), 283 (6700) nm; ECD (0.15 mM, MeOH) λ_{max} (Δε) 245 (7.2), 285 (7.8); IR ν_{max} 3350, 2930, 2855, 1665, 1600, 1540, 1460, 1400, 1380, 1250 cm^{−1}; ¹H and ¹³C NMR data, Table 5; ¹H NMR (CD₃OD, 500 MHz, 298 K): δ 4.09 (s, H-1), 6.41 (s, H-5), 3.75 (d, *J* = 18.0, H-7), 3.06 (d, *J* = 18.0, H-7), 3.74 (m, H-10), 3.40 (m, H-10), 4.76 (dd, *J* = 4.7; 7.2, H-11), 7.62 (s, H-13, H-13'), 4.07 (t, *J* = 6.5; 6.5, H-16), 2.11 (m, H-17), 2.87 (m, H-18), 2.47 (s, H-19), 2.47 (s, H-20), 3.73 (s, OMe); ¹³C NMR (CD₃OD, 125 MHz, 298 K): δ 74.2 (C-1), 112.6 (C-2), 147.9 (C-3), 121.5 (C-4), 130.7 (C-5), 91.1 (C-6), 38.3 (C-7), 153.0 (C-8), 160.8 (C-9), 47.3 (C-10), 70.1 (C-11), 142.5 (C-12), 130.2 (C-13, C-13'), 117.6 (C-14, C14'), 152.1 (C-15), 70.8 (C-16), 26.5 (C-17), 56.0 (C-18), 43.8 (C-19), 43.8 (C-20), 59.0 (OMe); HRESIMS *m/z* 761.8695 [M+H]⁺ (calc. for C₂₃H₂₈Br₄N₃O₆, 761.8671).

17-deoxy-11-*epi*-fistularin-3 (10): yellow amorphous solid (8 mg); [α]_D²⁵ +71.0 (*c* 0.3, MeOH); [α]_D²⁵ +20.0 (*c* 0.2, acetone); ECD (0.15 mM, MeOH) λ_{max} (Δε) 251 (7.7), 286 (7.6); ¹H NMR (acetone-*d*₆, 500 MHz, 298 K): δ 7.74 (s, 1H, NH), 7.63 (s, 1H, NH'), 7.52 (s, 2H, H-15, H-15'), 6.52 (d, *J* = 11.0 Hz, 2H, H-5, H-5'), 5.45 (br s, 2H, OH-1, OH-1'), 4.47 (br s, 1H, OH-11), 4.24 (m, 1H, H-11), 4.18 (d, *J* = 13 Hz, 2H, H-1, H-1'), 4.03 (m, 2H, H-12), 3.86 (d, *J* = 18.6 Hz, 1H, H-7), 3.82 (d, *J* = 18.6 Hz, 1H, H-7'), 3.78 (m, 1H, H-10a), 3.73 (s, 6H, OCH₃), 3.57 (dd, *J* = 7.0, 13 Hz, 2H, H-18), 3.52 (m, 1H, H-10b), 3.20 (d, *J* = 18.6 Hz, 1H, H-7), 3.15 (d, *J* = 18.6 Hz, 1H, H-7'), 2.88 (t, dd, *J* = 7.0, 13 Hz, H-17); HRESIMS *m/z* 1096.6923 [M−H][−] (calc. for C₃₁H₂₉Br₆N₄O₁₀, 1096.6923).

General acid hydrolysis of compounds **1**, **2**, **3**, **8**, and **10** for the preparation of the 1-aminodiol for Marfey derivatization: the compounds (2 mg of each) were dissolved in a mixture of TFA/H₂O (2/1, 2 mL) and heated in a closed tube at 120 °C for 36 h. Each solution was evaporated to dryness to obtain the corresponding crude hydrolysate.

Determination of C-11 Configuration for epi-fistularin-3 (**1**):

(a) Marfey derivatization: the hydrolysate was dissolved in water (100 µL) and combined with 1-fluoro-2,4-dinitrophenyl-5-L-alaninamide (L-FDAA) (1% w/v in acetone, 100 µL) and aqueous NaHCO₃ (1.0 M, 40 µL). The solution was heated at 60 °C for 5 min, then cooled. The mixture was filtered on 0.2 µm Millex-LG. Standards (*R*) and (*S*)-3-amino-1,2-propanediol were converted to their L-FDAA derivatives following the same procedure.

(b) LC analysis: the solutions of DAA derivatives were analyzed directly by UPLC/MS using HSS C18 column and eluted with H₂O + 0.1% HCOOH/CH₃CN + 0.1% HCOOH (98/2 to 70/30 in 10 min). The (*R*)- and (*S*)-DAA derivatives of 3-amino-1,2-propanediol were eluted at R_T = 6.59 min and R_T = 6.68 min, respectively. Analysis of 1-L-DAA derivative gave a retention time of R_T = 6.58 min, corresponding to an 11R configuration for epi-fistularin-3 (**1**).

Determination of C-11 Configuration for Compounds **2** and **3**.

(a) Marfey derivatization: the hydrolysate was dissolved in water (100 µL) and combined with 1-fluoro-2,4-dinitrophenyl-5-L-alaninamide (L-FDAA) (1% w/v in acetone, 100 µL) and aqueous NaHCO₃ (1.0 M, 40 µL). The solution was heated at 60 °C for 5 min, then cooled. The mixture was filtered on 0.2 µm Millex-LG. Standards (*R*) and (*S*)-3-amino-1,2-propanediol were converted to their L-FDAA derivatives following the same procedure.

(b) LC analysis: the solutions of DAA derivatives were analyzed directly by UPLC/MS using HSS C18 column and eluted with H₂O + 0.1% HCOOH/CH₃CN + 0.1% HCOOH (98/2 to 70/30 in 10 min). The (*R*)- and (*S*)-DAA derivatives of 3-amino-1,2-propanediol were eluted at R_T = 7.01 min and R_T = 7.10 min, respectively. Analysis of the compound L-DAA derivative gave a retention time of R_T = 7.01 min, corresponding to an 11R configuration for compounds **2** and **3**.

Determination of C-11 Configuration for Compound **8**

(a) Marfey derivatization: the hydrolysate was dissolved in water (100 µL) and combined with 1-fluoro-2,4-dinitrophenyl-5-L-alaninamide (L-FDAA) (1% w/v in acetone, 100 µL) and aqueous NaHCO₃ (1.0 M, 40 µL). The solution was heated at 60 °C for 5 min, then cooled. The mixture was filtered on 0.2 µm Millex-LG. Standards (*R*) and (*S*)-3-amino-1,2-propanediol were converted to their L-FDAA derivatives following the same procedure.

(b) LC analysis: the solutions of DAA derivatives were analyzed directly by UPLC/MS using HSS C18 column and eluted with H₂O + 0.1% HCOOH/CH₃CN + 0.1% HCOOH (98/2 to 70/30 in 10 min). The (*R*)- and (*S*)-DAA derivatives of 3-amino-1,2-propanediol were eluted at R_T = 10.14 min and R_T = 10.30 min, respectively. Analysis of 8-L-DAA derivative gave a retention time of R_T = 10.13 min, corresponding to an 11R configuration for compound **8**.

Determination of C-11 Configuration for 17-deoxy-epi-fistularin-3 (**10**)

(a) Marfey derivatization: the hydrolysate was dissolved in water (100 µL) and combined with 1-fluoro-2,4-dinitrophenyl-5-L-alaninamide (L-FDAA) (1% w/v in acetone, 100 µL) and aqueous NaHCO₃ (1.0 M, 40 µL). The solution was heated at 60 °C for 5 min, then cooled. The mixture was filtered on 0.2 µm Millex-LG. Standards (*R*) and (*S*)-3-amino-1,2-propanediol were converted to their L-FDAA derivatives following the same procedure.

(b) LC analysis: the solutions of DAA derivatives were analyzed directly by UPLC/MS using HSS C18 column and eluted with H₂O + 0.1% HCOOH/CH₃CN + 0.1% HCOOH (98/2 to 70/30 in 10 min). The (*R*)- and (*S*)-DAA derivatives of 3-amino-1,2-propanediol were eluted at $R_T = 6.78$ min and $R_T = 6.88$ min, respectively. Analysis of 10-L-DAA derivative gave a retention time of $R_T = 6.80$ min, corresponding to an 11*R* configuration for 17-deoxy-*epi*-fistularin-3 (10).

Conversion of 11-*epi*-fistularin-3 (1) to compounds 2–7 and agelorins A/B: compound 1 was dissolved in a mixture 1/1 of acetonitrile (+0.1% HCOOH)/water (+0.1% HCOOH) and stored at room temperature for two weeks. The reaction mixture was then dried under vacuum and submitted for HPLC analysis. Compound 1 gave agelorin A, agelorin B, and the compounds 2–7 by comparison with the retention time of each product.

4.4. Antibacterial Bioassay

Preparation of the compounds: antifouling efficiency of the compounds was assessed towards the inhibition of growth of key bacteria involved in marine and terrestrial surface colonisation. All bioassays were run in six replicates and using two batches of organisms. Compounds were tested at 0.01, 0.1, and 1 µg/mL. 96 well-plates were used and were coated with the compounds. Methanol was used as a carrier solvent and after its evaporation plates were sterilized under UV exposure for 30 min [41].

4.4.1. Biological Material

Seven strains of marine bacteria i.e., *Halomonas aquamarina* (ATCC 14400), *Polaribacter irgensii* (ATCC 700398), *Shewanella putrefaciens* (ATCC 8071), *Roseobacter littoralis* (ATCC 495666), *Pseudoalteromonas elyakovii* (ATCC 700519), *Vibrio aestuarianus* (ATCC 35048), *Vibrio natriegens* (ATCC 14058), and three strains of terrestrial bacteria, i.e., *Escherichia coli* (ATCC 11775), *Staphylococcus aureus* (ATCC 126000), and *Pseudomonas aeruginosa* (ATCC 16145) were used to assess the antibacterial potency of the compounds.

For maintenance, bacterial strains were kept on solid media: autoclaved seawater, 0.5% peptone (oxid), and 1% agar for marine strains [51].

4.4.2. Bioassay

Inhibition of bacterial growth: experiments were run as previously described by Maréchal et al. [52]. 96-well plates containing the compounds were inoculated with the bacteria (2×10^8 cells/mL) in LB medium (Luria Hinton Broth, Sigma, Andover, UK), (supplemented with NaCl (35 g/L) for marine strains), at 30 °C for 48 h. After incubation, the intensity of growth in the presence of the tested compounds and control (media only) was assessed by measurement of the OD 620 nm using a spectrophotometer (Apollo LB912, Berthold Technologies). Results are expressed as minimum inhibitory concentrations (MIC values).

4.5. Acetylcholinesterase Inhibition Bioassay

This bioassay was set up after Ellman [53]. This method is the most commonly used to screen compounds against this target. All reagents, buffers, and salts were purchased from Sigma-Aldrich (Saint-Louis, MO, USA). Two buffer solutions were prepared extemporaneously: buffer A (50 mM Tris-HCl pH 8 + 0.1% BSA); and buffer B (50 mM Tris-HCl pH 8 + 0.1 M NaCl + 0.02 M MgCl₂·6H₂O). Acetylcholinesterase from *Electrophorus electricus* (EC 3.1.1.7, AChE—0.2 U/mL) was dissolved in buffer A, 5,5'-dithiobis-2-nitrobenzoic acid (DTNB-Ellman's reagent—3 mM) in buffer B, and acetylthiocholine iodide (ACTI—6 mM) in H₂O. Tested compounds were dissolved in DMSO at 10 mg/mL, stored at −20 °C, and subsequently 100 times diluted in H₂O before the assay. 10 µL AChE was preincubated for 10 min with 70 µL DTNB and 10 µL compounds solution in 96-well microplates. The enzymatic reaction was initiated with the addition of 10 µL ACTI, a synthetic substrate of AChE. After 30 min at 25 °C, absorbance of the plate was measured at 405 nm using a microplate reader (Tecan Infinite M200). Percentage of inhibition was calculated using the

following equation: $100 \times (A_{\text{control}} - A_{\text{sample}}) / (A_{\text{control}} - A_0)$, where A_{control} is the average absorbance of the wells in which tested compounds were replaced by water, A_{sample} is the absorbance of the well with tested compound, and A_0 the average absorbance of blank wells where AChE was omitted. Products leading to 50% inhibition of AChE were then submitted to dose-response experiments. Serial dilutions of the products were prepared (100, 50, 25, 12.5, 6.25, 3.125, 1.5625, and 0.78125 $\mu\text{g}/\text{mL}$). Enzymatic assay was performed according to the same procedure with 10 μL of each concentration added. IC_{50} values (concentration leading to 50% inhibition of enzymatic activity) were graphically determined by plotting the percentage of inhibition against the compound concentrations.

Each assay was performed in triplicate and results are expressed as mean values \pm SD.

4.6. DNMT1 Activity Inhibition Bioassay

DNMT1 activity was measured using in vitro DNMT activity/inhibition assay (Active Motif, Rixensart, Belgium) according to manufacturer's instructions. All compounds were used at a final 50 μM concentration. The methylation reaction was performed by incubating 25 ng of purified DNMT1 with compounds for 2 h at 37 $^{\circ}\text{C}$ in the presence of 0.01% Triton X-100. The methylated DNA was then recognized by the His-tagged methyl-CpG binding domain protein 2b. The addition of a poly-histidine antibody conjugated to horseradish peroxidase provided a colorimetric readout quantified with a spectrophotometer (SpectraCount, Packard) at the wavelength of 450 nm. Data of DNMT1 activity are reported as percentage of control.

Supplementary Materials: The following are available online at <https://www.mdpi.com/1660-3397/19/3/143/s1>: Spectroscopic data (HRMS, ^1H NMR, ^{13}C NMR, COSY, HSQC, ECD, and HMBC spectra) for compounds 1–10.

Author Contributions: A.A.-M. and C.D. conceived and directed the project. A.A.-M. supervised the findings of this work and prepared the manuscript. C.D. and S.P. organized the field work and sponge collection, the conditioning and the realization of the library of extracts in preliminary to this thorough study, and participated in the correction of the final version of the manuscript. C.M. and D.L. did the major chemical experimental part including isolation and structural identification of the compounds and wrote the first experimental draft of the manuscript. C.M. solved several determining points for this paper. A.E.-D. participated in the project occasionally and read the manuscript. The biological assays were designed and performed by R.T. and C.H. (antibacterial bioassay), T.M.L. (Acetylcholinesterase inhibition), and C.F. and M.D. (DNMT1 activity inhibition). All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by CNRS, IRD and AFD (grant CZZ 3012.01 T).

Acknowledgments: This work is part of the C2 component of the CRISP (Coral Reef Initiative in the South Pacific) project and granted by the Agence Française de Développement (grant CZZ 3012.01 T, AFD). We thank John N.A. Hooper for the identification of the sponges. We thank the Solomon Islands government for allowing us to collect in their country, the Fisheries Department and R. Sulu (University of the South Pacific in Honiara) for their help and assistance. We acknowledge C. Payri (IRD-Université de Polynésie Française), the crew of the R/V ALIS, and IRD's diving team (SEOH IRD Noumea, New Caledonia) for their essential contribution to the field trip. We thank John N.A. Hooper for the identification of the sponges.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Kornprobst, J.M. *Encyclopedia of Marine Natural Products*; Wiley-Blackwell: Weinheim, Germany, 2010; ISBN 978-3-527-32703-4.
2. Nuñez, C.V.; de Almada, E.V.R.; Granato, A.C.; Marques, S.O.; Santos, K.O.; Pereira, F.R.; Macedo, M.L.; Ferreira, A.G.; Hajdu, E.; Pinheiro, U.S.; et al. Chemical variability within the marine sponge *Aplysina fulva*. *Biochem. Syst. Ecol.* **2008**, *36*, 283–296.
3. Nicacio, K.J.; Ioca, L.P.; Froes, A.M.; Leomil, L.; Appolinario, L.R.; Thompson, C.C.; Thompson, F.L.; Ferreira, A.G.; Williams, D.E.; Andersen, R.J.; et al. Cultures of the Marine Bacterium *Pseudovibrio denitrificans* Ab134 Produce Bromotyrosine-Derived Alkaloids Previously Only Isolated from Marine Sponges. *J. Nat. Prod.* **2017**, *80*, 235–240. [[CrossRef](#)] [[PubMed](#)]
4. König, G.M.; Wright, A.D. Agelorins A and B, and 11-*epi*-fistularin-3, three new antibacterial fistularin-3 derivatives from the tropical marine sponge *Agelas oroides*. *Heterocycles* **1993**, *36*, 1351–1358.

5. Ebel, R.; Brenzinger, M.; Kunze, A.; Gross, H.J.; Proksch, P. Wound Activation of Protoxins in Marine Sponge *Aplysina Aerophobaj*. *Chem. Ecol.* **1997**, *23*, 1451–1462. [[CrossRef](#)]
6. Thoms, C.; Wolff, M.; Padmakumar, K.; Ebel, R.; Proksch, P. Chemical Defense of Mediterranean Sponges *Aplysina cavernicola* and *Aplysina aerophoba*. *Z. Für Nat. C* **2004**, *59*, 113–122. [[CrossRef](#)] [[PubMed](#)]
7. Yang, X.; Davis, R.A.; Buchanan, M.S.; Duffy, S.; Avery, V.M.; Camp, D.; Quinn, R.J. Antimalarial Bromotyrosine Derivatives from the Australian Marine Sponge *Hyattella* sp. *J. Nat. Prod.* **2010**, *73*, 985–987. [[CrossRef](#)]
8. Diers, J.A.; Pennaka, H.K.; Peng, J.; Bowling, J.J.; Duke, S.O.; Hamann, M.T. Structural Activity Relationship Studies of Zebra Mussel Antifouling and Antimicrobial Agents from Verongid Sponges. *J. Nat. Prod.* **2004**, *67*, 2117–2120. [[CrossRef](#)] [[PubMed](#)]
9. Tsukamoto, S.; Kato, H.; Hirota, H.; Fusetani, N. Ceratinamides A and B: New antifouling dibromotyrosine derivatives from the marine sponge *Pseudoceratina purpurea*. *Tetrahedron* **1996**, *52*, 8181–8186. [[CrossRef](#)]
10. Lebouvier, N.; Jullian, V.; Desvignes, I.; Maurel, S.; Parenty, A.; Dorin-Semblat, D.; Doerig, C.; Sauvain, M.; Laurent, D. Antiplasmodial Activities of Homogentisic Acid Derivative Protein Kinase Inhibitors Isolated from a Vanuatu Marine Sponge *Pseudoceratina* sp. *Mar. Drugs* **2009**, *7*, 640–653. [[CrossRef](#)] [[PubMed](#)]
11. Oliveira, M.F.; de Oliveira, J.H.H.L.; de Galetti, F.C.S.; Souza, A.O.; de Silva, C.L.; Hajdu, E.; Peixinho, S.; Berlinck, R.G.S. Antimycobacterial Brominated Metabolites from Two Species of Marine Sponges. *Planta Med.* **2006**, *72*, 437–441. [[CrossRef](#)]
12. Gunasekera, S.P.; Cross, S.S. Fistularin 3 and 11-Ketofistularin 3. Feline Leukemia Virus Active Bromotyrosine Metabolites from the Marine Sponge *Aplysina archeri*. *J. Nat. Prod.* **1992**, *55*, 509–512. [[CrossRef](#)]
13. Ross, S.A.; Weete, J.D.; Schinazi, R.F.; Wirtz, S.S.; Tharnish, P.; Scheuer, P.J.; Hamann, M.T.; Mololipids, A. New Series of Anti-HIV Bromotyramine-Derived Compounds from a Sponge of the Order Verongiida. *J. Nat. Prod.* **2000**, *63*, 501–503. [[CrossRef](#)] [[PubMed](#)]
14. Kernan, M.R.; Cambie, R.C.; Bergquist, P.R. Chemistry of Sponges, VII. 11,19-Dideoxyfistularin 3 and 11-Hydroxyaerotionin, Bromotyrosine Derivatives from *Pseudoceratina durissima*. *J. Nat. Prod.* **1990**, *53*, 615–622. [[CrossRef](#)]
15. Koulman, A.; Proksch, P.; Ebel, R.; Beekman, A.C.; van Uden, W.; Konings, A.W.T.; Pedersen, J.A.; Pras, N.; Woerdenbag, H.J. Cytotoxicity and Mode of Action of Aeroplysinin-1 and a Related Dienone from the Sponge *Aplysina Aerophoba*. *J. Nat. Prod.* **1996**, *59*, 591–594. [[CrossRef](#)] [[PubMed](#)]
16. Mierzwa, R.; King, A.; Conover, M.A.; Tozzi, S.; Puar, M.S.; Patel, M.; Coval, S.J.; Pomponi, S.A. Verongamine, a Novel Bromotyrosine-Derived Histamine H3-Antagonist from the Marine Sponge *Verongula gigantean*. *J. Nat. Prod.* **1994**, *57*, 175–177. [[CrossRef](#)]
17. Kobayashi, J.; Honma, K.; Sasaki, T.; Tsuda, M. Pseudolipids J-R, New Bromotyrosine Alkaloids from the Okinawan Marine Sponge *Psammaphysilla pura*. *Chem. Pharm. Bull.* **1995**, *43*, 403–407. [[CrossRef](#)]
18. Sallam, A.A.; Ramasahayam, S.; Meyer, S.A.; Sayed, K.A.E. Design, synthesis, and biological evaluation of dibromotyrosine analogues inspired by marine natural products as inhibitors of human prostate cancer proliferation, invasion, and migration. *Bioorganic Med. Chem.* **2010**, *18*, 7446–7457. [[CrossRef](#)] [[PubMed](#)]
19. El-Demerdash, A.; Moriou, C.; Toullec, J.; Besson, M.; Soulet, S.; Schmitt, N.; Petek, S.; Lecchini, D.; Debitus, C.; Al-Mourabit, A. Bioactive Bromotyrosine-Derived Alkaloids from the Polynesian Sponge *Suberea ianthelliformis*. *Mar. Drugs* **2018**, *16*, 146. [[CrossRef](#)] [[PubMed](#)]
20. Quinn, R.J.; Buchanan, M.S.; Carroll, A.R.; Wessling, D.; Jobling, M.; Avery, V.M.; Davis, R.A.; Feng, Y.; Xue, Y.; Öster, L.; et al. A sponge with the same name *Suberea clavata* was chemically studied. *Med. Chem.* **2008**, *51*, 3583–3587.
21. Buchanan, M.S.; Carroll, A.R.; Wessling, D.; Jobling, M.; Avery, V.M.; Davis, R.A.; Feng, Y.; Hooper, J.N.A.; Quinn, R.J.J. Clavatadines C–E, Guanidine Alkaloids from the Australian Sponge *Suberea clavata*. *Nat. Prod.* **2009**, *72*, 973–975. [[CrossRef](#)] [[PubMed](#)]
22. Mancini, I.; Guella, G.; Laboute, P.; Debitus, C.; Pietra, F. Hemifistularin 3: A degraded peptide or biogenetic precursor? Isolation from a sponge of the order verongiida from the coral sea or generation from base treatment of 11-oxofistularin 3. *J. Chem. Soc. Perkin Trans.* **1993**, *1*, 3121–3125. [[CrossRef](#)]
23. Compagnone, R.S.; Avila, R.; Suárez, A.I.; Abrams, O.V.; Rangel, H.R.; Arvelo, F.; Piña, I.C.; Merentes, E. 11-Deoxyfistularin-3, a New Cytotoxic Metabolite from the Caribbean Sponge *Aplysina fistularis insularis*. *J. Nat. Prod.* **1999**, *62*, 1443–1444. [[CrossRef](#)] [[PubMed](#)]
24. Gunasekera, M.; Gunasekera, S.P. Dihydroxyaerotionin and Aerophobin 1. Two Brominated Tyrosine Metabolites from the Deep Water Marine Sponge *Verongula rigida*. *J. Nat. Prod.* **1989**, *52*, 753–756. [[CrossRef](#)]
25. Kossuga, M.H.; MacMillan, J.B.; Rogers, E.W.; Molinski, T.F.; Nascimento, G.G.F.; Rocha, R.M.; Berlinck, R.G.S. (2S,3R)-2-Aminododecan-3-ol, a New Antifungal Agent from the Ascidian *Clavelina oblonga*. *J. Nat. Prod.* **2004**, *67*, 1879–1881. [[CrossRef](#)]
26. Shaker, K.H.; Zinecker, H.; Ghani, M.A.; Imhoff, J.F.; Schneider, B. Bioactive Metabolites from the Sponge *Suberea* sp. *Chem. Biodivers.* **2010**, *7*, 2880–2887. [[CrossRef](#)] [[PubMed](#)]
27. Tran, T.D.; Pham, N.B.; Fechner, G.; Hooper, J.N.A.; Quinn, R.J. Bromotyrosine Alkaloids from the Australian Marine Sponge *Pseudoceratina verrucosa*. *J. Nat. Prod.* **2013**, *76*, 516–523. [[CrossRef](#)]
28. Florean, C.; Kim, K.R.; Schnekenburger, M.; Kim, H.-J.; Moriou, C.; Debitus, C.; Dicato, M.; Al-Mourabit, A.; Han, B.W.; Diederich, M. Synergistic AML Cell Death Induction by Marine Cytotoxin (+)-1(R), 6(S), 1'(R), 6'(S), 11(R), 17(S)-Fistularin-3 and Bcl-2 Inhibitor Venetoclax. *Mar. Drugs* **2018**, *16*, 518. [[CrossRef](#)] [[PubMed](#)]

29. Rogers, E.W.; de Oliveira, M.F.; Berlinck, R.G.; Konig, G.M.; Molinski, T.F. Stereochemical heterogeneity in Verongid sponge metabolites. Absolute stereochemistry of (+)-fistularin-3 and (+)-11-*epi*-fistularin-3 by microscale LCMS-Marfey's analysis. *J. Nat. Prod.* **2005**, *68*, 891–896. [[CrossRef](#)]
30. Peng, J.; Li, J.; Hamann, M.T. The Marine Bromotyrosine Derivatives. *Alkaloids Chem. Biol.* **2005**, *61*, 59–262.
31. Me Millan, J.A.; Paul, I.C.; Goo, Y.M.; Rinehart, K.L.; Krueger, W.C.; Pschigoda, L.M. An x-ray study of aerothionin from *Aplysina fistularis* (PALLAS). *Tetrahedron Lett.* **1981**, *22*, 39–42. [[CrossRef](#)]
32. Wang, Q.; Tang, X.L.; Luo, X.C.; de Voog, N.J.; Li, P.L.; Li, G.Q. Aplysinopsin-type and Bromotyrosine-derived Alkaloids from the South China Sea Sponge *Fascaplysinopsis reticulata*. *Sci. Rep.* **2019**, *9*, 2248. [[CrossRef](#)]
33. Hoye, T.R.; Jeffrey, J.; Shao, F. Mosher ester analysis for the determination of absolute configuration of stereogenic (chiral) carbinol carbons. *Nat. Protoc.* **2007**, *2*, 2451–2458. [[CrossRef](#)] [[PubMed](#)]
34. Zhou, Y.; Debbab, A.; Wray, V.; Lin, W.; Schulz, B.; Trepos, R.; Pile, C.; Hellio, C.; Proksch, P.; Aly, A.H. Marine bacterial inhibitors from the sponge-derived fungus *Aspergillus* sp. *Tetrahedron Lett.* **2014**, *55*, 2789–2792. [[CrossRef](#)]
35. Von Baum, H.; Marre, R. Antimicrobial resistance of *Escherichia coli* and therapeutic implications. *Int. J. Med. Microbiol.* **2005**, *295*, 503–511. [[CrossRef](#)]
36. Labreuche, Y.; Soudant, P.; Gonçalves, M.; Lambert, C.; Nicolas, J.-L. Effects of extracellular products from the pathogenic *Vibrio aestuarianus* strain 01/32 on lethality and cellular immune responses of the oyster *Crassostrea gigas*. *Dev. Comp. Immunol.* **2006**, *30*, 367–379. [[CrossRef](#)]
37. Labreuche, Y.; Lambert, C.; Soudant, P.; Boulo, V.; Huvet, A.; Nicolas, J.-L. Cellular and molecular hemocyte responses of the Pacific oyster, *Crassostrea gigas*, following bacterial infection with *Vibrio aestuarianus* strain 01/32. *Microbes Infect.* **2006**, *8*, 2715–2724. [[CrossRef](#)] [[PubMed](#)]
38. Labreuche, Y.; Le Roux, F.; Henry, J.; Zatylny, C.; Huvet, A.; Lambert, C.; Soudant, P.; Mazel, D.; Nicolas, J.-L. *Vibrio aestuarianus* zinc metalloprotease causes lethality in the Pacific oyster *Crassostrea gigas* and impairs the host cellular immune defenses. *Fish Shellfish.* **2010**, *29*, 753–758. [[CrossRef](#)]
39. Cochenne-Laureau, N.; Baud, J.-P.; Pepin, J.-F.; Benabdelmouna, A.; Soletchnik, P.; Lupo, C.; Garcia, C.; Arzul, I.; Boudry, P.; Huvet, A.; et al. Les Surmortalités des Naissains D'huîtres Creuses, *Crassostrea Gigas*: Acquis des Recherches en 2010. RST/LER/MPL/11.07. 2011. Available online: <https://archimer.ifremer.fr/doc/00033/14423/> (accessed on 25 February 2021).
40. Qurashi, A.W.; Sabri, A.N. Biofilm formation in moderately halophilic bacteria is influenced by varying salinity levels. *J. Basic Microbiol.* **2012**, *52*, 566–572. [[CrossRef](#)]
41. Chambers, L.D.; Hellio, C.; Stokes, K.R.; Dennington, S.P.; Goodes, L.R.; Wood, R.J.K.; Walsh, F.C. Investigation of *Chondrus crispus* as a potential source of new antifouling agents. *Int. Biodeterior. Biodegrad.* **2011**, *65*, 939–946. [[CrossRef](#)]
42. Austin, B.; Rodgers, C.J.; Forn, J.M.; Colwell, R.R. *Alcaligenes faecalis* subsp. *homari* subsp. nov., a New Group of Bacteria Isolated from Moribund Lobsters. *Int. J. Syst. Bacteriol.* **1981**, *31*, 72–76. [[CrossRef](#)]
43. Drake, L.A.; Meyer, A.E.; Forsberg, R.L.; Baier, R.E.; Doblin, M.A.; Heinemann, S.; Johnson, W.P.; Koch, M.; Rublee, P.A.; Dobbs, F.C. Potential Invasion of Microorganisms and Pathogens via 'Interior Hull Fouling': Biofilms Inside Ballast Water Tanks. *Biol. Invasions* **2005**, *7*, 969–982. [[CrossRef](#)]
44. Huchard, E.; Martinez, M.; Alout, H.; Douzery, E.J.P.; Lutfalla, G.; Berthomieu, A.; Berticat, C.; Raymond, M.; Weill, M. Acetylcholinesterase genes within the Diptera: Takeover and loss in true flies. *Proc. R. Soc. B Biol. Sci.* **2006**, *273*, 2595–2604. [[CrossRef](#)] [[PubMed](#)]
45. Ilg, T.; Cramer, J.; Lutz, J.; Noack, S.; Schmitt, H.; Williams, H.; Newton, T. The characterization of *Lucilia cuprina* acetylcholinesterase as a drug target, and the identification of novel inhibitors by high throughput screening. *Insect Biochem. Mol. Biol.* **2011**, *41*, 470–483. [[CrossRef](#)] [[PubMed](#)]
46. Rickwood, C.J.; Galloway, T.S. Acetylcholinesterase inhibition as a biomarker of adverse effect: A study of *Mytilus edulis* exposed to the priority pollutant chlorfenvinphos. *Aquat. Toxicol.* **2004**, *67*, 45–56. [[CrossRef](#)]
47. Faimali, M.; Falugi, C.; Gallus, L.; Piazza, V.; Tagliaferro, G. Involvement of Acetyl Choline in Settlement of *Balanus Amphitrite*. *Biofouling* **2003**, *19*, 213–220. [[CrossRef](#)]
48. Piazza, V.; Dragić, I.; Sepčić, K.; Faimali, M.; Garaventa, F.; Turk, T.; Berne, S. Antifouling Activity of Synthetic Alkylpyridinium Polymers Using the Barnacle Model. *Mar. Drugs* **2014**, *12*, 1959–1976. [[CrossRef](#)]
49. Florean, C.; Schnekenburger, M.; Lee, J.; Kim, K.R.; Mazumder, A.; Song, S.; Kim, J.-M.; Grandjennette, C.; Kim, J.-G.; Yoon, A.-Y.; et al. Discovery and characterization of Isofistularin-3, a marine brominated alkaloid, as a new DNA demethylating agent inducing cell cycle arrest and sensitization to TRAIL in cancer cells. *Oncotarget* **2016**, *7*, 24027–24049. [[CrossRef](#)]
50. Payri, C. BSMS-1 cruise. *RV Alis*. **2004**. [[CrossRef](#)]
51. Plouguerne, E.; Ioannou, E.; Georgantea, P.; Vagias, C.; Roussis, V.; Hellio, C.; Kraffe, E.; Stiger-Pouvreau, V. Anti-microfouling Activity of Lipidic Metabolites from the Invasive Brown Alga *Sargassum muticum* (Yendo) Fensholt. *Mar. Biotechnol.* **2010**, *12*, 52–61. [[CrossRef](#)]
52. Maréchal, J.-P.; Culioli, G.; Hellio, C.; Thomas-Guyon, H.; Callow, M.E.; Clare, A.S.; Ortalo-Magné, A. Seasonal variation in antifouling activity of crude extracts of the brown alga *Bifurcaria bifurcata* (Cystoseiraceae) against cyprids of *Balanus amphitrite* and the marine bacteria *Cobetia marina* and *Pseudoalteromonas haloplanktis*. *J. Exp. Mar. Biol. Ecol.* **2004**, *313*, 47–62. [[CrossRef](#)]
53. Ellman, G.L.; Courtney, K.D.; Andres, V.; Featherstone, R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. *Biochem. Pharmacol.* **1961**, *7*, 88–95. [[CrossRef](#)]